Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tourmaline Bio (TRML)
NASDAQ:TRML
Holding TRML?
Track your performance easily
TRML Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.18 - $48.31
Previous Close$23.02
Volume703.22K
Average Volume (3M)238.10K
Market Cap
$590.26M
Enterprise Value$301.06M
Total Cash (Recent Filing)$289.53M
Total Debt (Recent Filing)$333.00K
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Aug 08, 2024EPS Estimate
-$0.71Last Dividend Ex-Date
Oct 20, 2023Dividend Yield65.67%
Share Statistics
EPS (TTM)-3.68
Shares Outstanding25,641,363
10 Day Avg. Volume249,664
30 Day Avg. Volume238,096
Standard Deviation0.27
R-Squared0.15
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.75
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-6.27
Forecast
1Y Price Target
$54.00Price Target Upside134.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Tourmaline Bio News
PremiumCompany Announcements
Tourmaline Bio’s Chief Medical Officer Resigns AmicablyPremiumCompany Announcements
Tourmaline Bio Showcases Promising Candidate in Updated Presentation
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe upcoming Phase 3 pivotal trial for TOUR006 as a first-line treatment for thyroid eye disease signifies progress in the company's clinical development pipeline.
Financial PerformanceNet loss was $13.3M, or ($0.55) per share, lower than the estimated loss of $16.0M.
Regulatory MilestonesReceiving IND clearance for the Phase 2 trial of TOUR006 in cardiovascular disease suggests regulatory confidence in the company's research and potential for expanding treatment applications.
Bears Say
Clinical Trial ResultsRecent disappointing data from Chugai’s Phase 3 LUMINESCE trial of satralizumab (anti-IL-6) in myasthenia gravis (MG) has pressured TRML shares.
Financial PerformanceNet loss totaled $42.1M in 2023.
Share Price PerformanceThe recent drop in TRML share price as a result of the data from the Phase 3 LUMINESCE trial of Enspryng (satralizumab, an anti-IL-6 antibody) in generalized myasthenia gravis (gMG) is unwarranted.
---
Ownership Overview
Currently, No data available
---
TRML FAQ
What was Tourmaline Bio’s price range in the past 12 months?
Tourmaline Bio lowest stock price was $9.18 and its highest was $48.31 in the past 12 months.
What is Tourmaline Bio’s market cap?
Currently, no data Available
When is Tourmaline Bio’s upcoming earnings report date?
Tourmaline Bio’s upcoming earnings report date is Aug 08, 2024 which is 76 days ago.
How were Tourmaline Bio’s earnings last quarter?
Tourmaline Bio released its earnings results on May 13, 2024. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.668 by $0.118.
Is Tourmaline Bio overvalued?
According to Wall Street analysts Tourmaline Bio’s price is currently Undervalued.
Does Tourmaline Bio pay dividends?
Tourmaline Bio pays a Notavailable dividend of $1.51 which represents an annual dividend yield of 65.67%. See more information on Tourmaline Bio dividends here
What is Tourmaline Bio’s EPS estimate?
Tourmaline Bio’s EPS estimate is -$0.71.
How many shares outstanding does Tourmaline Bio have?
Tourmaline Bio has 25,641,363 shares outstanding.
What happened to Tourmaline Bio’s price movement after its last earnings report?
Tourmaline Bio reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.668. Following the earnings report the stock price went up 6.131%.
Which hedge fund is a major shareholder of Tourmaline Bio?
Among the largest hedge funds holding Tourmaline Bio’s share is RA Capital Management. It holds Tourmaline Bio’s shares valued at 33M.
---
Tourmaline Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.00 (134.58% Upside)
$54.00 (134.58% Upside)
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $98.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
81.21%
12-Months-Change
Fundamentals
Return on Equity
-20.84%
Trailing 12-Months
Asset Growth
116.68%
Trailing 12-Months
Company Description
Tourmaline Bio
Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.
---
TRML Stock 12 Month Forecast
Average Price Target
$54.00
▲(134.58% Upside)
Technical Analysis
Best Analysts Covering TRML
1 Year
1 Year Success Rate
4/4 ratings generated profit
1 Year Average Return
+47.20%
reiterated a buy rating last month
Copying Srikripa Devarakonda's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +47.20% per trade.
---